ORIC Pharmaceuticals, Inc.
ORICHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ORIC Pharmaceuticals, Inc. focuses on Biotechnology services and products. ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Valued at $1.37B, ORIC is a small-cap name in its sector. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Market Cap
$1.37B
Beta
0.98
P/E (TTM)
—
P/E (Fwd)
-7.87
EPS (TTM)
$-1.28
EPS (Fwd)
$-1.67
ROE
-39.8%
ROA
-26.0%
Cash
$264.8M
Total Debt
$6.0M
Free CF
-$68.8M
52W Change
0.5%
Annual Financials
Cash vs Debt
Where ORIC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ORIC finished 15.95% above its 150-day moving average ($10.97) and 15.11% above its 200-day moving average ($11.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ORIC overbought or oversold?
At the October 20, 2026 close, ORIC's RSI(14) was 43.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
ORIC Pharmaceuticals, Inc. holds $264.8M in cash against $6.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$68.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -39.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, ORIC has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ORIC Pharmaceuticals, Inc.'s trajectory.